Company intelligence / Profile preview

Phyxius Pharma

Morrisville, North Carolina, USA

Ownership: Private
Development stage: Other

Overview

Phyxius Pharma developed levosimendan for prevention/treatment of LCOS in cardiac surgery patients. The drug reached Phase 3 stage with FDA Fast Track and Special Protocol Assessment approvals, but the intellectual property and development rights were acquired by Oxygen Biotherapeutics before commercialization.

Therapeutic areas: Cardiovascular
Modalities: Small molecule (levosimendan)
Industry: Biotech

Partnerships

Orion Corporation (licensing rights for levosimendan in USA/Canada)

Beyond the preview

Go deeper on Phyxius Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phyxius Pharma.

Explore the full profile